Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 October;56(5) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 October;56(5):421-9

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 October;56(5):421-9

AN UPDATE ON MOLECULAR IMAGING OF PROSTATE CANCER (Part II) 

Lymph nodal metastases: diagnosis and treatment

Di Muzio N. 1, Fodor A. 1, Berardi G. 1, Mapelli P. 2, Gianolli L. 2, Messa C. 3, 5, Picchio M. 2, 3

1 Radiation Therapy, San Raffaele Scientific Institute, Milan, Italy;
2 Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy;
3 Institute for Bioimaging and Molecular Physiology, National Research Council (IBFM-CNR), Milan, Italy;
4 Tecnomed Foundation, University of Milano-Bicocca, Milan, Italy;
5 Nuclear Medicine, San Gerardo Hospital, Monza, Italy

High risk prostate cancer patients have a significant risk to develop regional lymph node metastases, and this represent a major cause of biochemical failure. Although pelvic lymphadenectomy is the gold standard to assess the status of pelvic lymph nodes, a diagnostic imaging tool to non-invasively explore patients and to detect metastases, both in staging and in re-staging phase, would be of particular help in clinical management. In staging phase, while choline PET/CT specificity has been reported to be fairly high in lymph nodal detection, its sensitivity is not adequate due to its spatial resolution. Its role in the evaluation of patients with biochemical relapse or with suspected relapse has been successfully documented. In particular, choline PET/CT has great potential as a single step whole body diagnostic procedure to evaluate lymph nodal and bone metastatic involvement. Salvage lymph nodal dissection was recently listed as a possible experimental option for patients with nodal recurrent prostate cancer, even in the absence of solid prospective data. Radiation treatment for lymph-node recurrence is a therapeutic option evaluated in several studies, in particular by using stereotactic treatment or whole pelvic lymph-nodal irradiation plus a boost on choline PET/CT positive lymph nodes. In the present review an analysis of the specific role of choline PET/CT in guiding a specific treatment on lymph nodal site in prostate cancer patients is reported.

language: English


FULL TEXT  REPRINTS

top of page